AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING 2018 Pre-ASCOCHICAGO, Report ILLINOIS • MAY 31 – JUNE 4, 2019 Cover page, paste image over entire page 2019 ASCO Planner May 2018 / 1 Information Classification: General NOT A PRODUCT SPONSORED BY ASCO 2019 ASCO Annual Meeting Planner Friday, May 31 - Oral Presentations Start End Title Drug Company Presenter Abstract # Clinical Science Symposium EGFR and ROS1: Targeting Resistance Location: Hall D1 1:00 PM 2:30 PM Chair - EGFR and ROS1: Targeting Resistance Gregory J. Riely 1:00 PM 2:30 PM Chair - EGFR and ROS1: Targeting Resistance Jose Maria Pacheco 1:00 PM 1:12 PM How Can We Overcome TKI Resistance in EGFR-Mutant NSCLC? Katerina A. Politi 1:12 PM 1:24 PM JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell JNJ-61186372 Johnson & Johnson Eric B. Haura 9009 lung cancer (NSCLC). 1:24 PM 1:36 PM Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in U3-1402 Daiichi Sankyo Pasi A. Janne 9010 EGFR TKI-resistant, EGFRm NSCLC. 1:36 PM 1:48 PM Using Antibodies in a TKI World Jessica Ruth Bauman 1:48 PM 2:00 PM Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion- repotrectinib Turning Point Byoung Chul Cho 9011 positive non-small cell lung cancer (TRIDENT-1 study). Therapeutics 2:00 PM 2:12 PM cROS1ng Barriers in Resistance Benjamin Besse 2:12 PM 2:30 PM Panel Question and Answer Panel Discussion Oral Abstract Session Genitourinary (Prostate) Cancer Location: Arie Crown Theater 2:45 PM 5:45 PM Chair - Genitourinary (Prostate) Cancer Joshi J. Alumkal 2:45 PM 5:45 PM Chair - Genitourinary (Prostate) Cancer Alan Haruo Bryce 2:45 PM 2:57 PM Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic darolutamide Bayer Karim Fizazi 5000 castrate-resistant prostate cancer (nmCRPC). 2:57 PM 3:09 PM Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for Christian Carrie 5001 metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475). 3:09 PM 3:21 PM PSMA heterogeneity and DNA repair defects in prostate cancer. Alec Paschalis 5002 3:21 PM 3:33 PM Therapeutic Advances, Balancing Quality of Life Daniel Eidelberg Spratt 3:33 PM 3:45 PM Panel Question and Answer Panel Discussion 3:45 PM 3:57 PM Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or Jevtana; Xtandi; Sanofi; Astellas; Kim N. Chi 5003 enzalutamide (ENZ) in poor prognosis metastatic CRPC. Zytiga Johnson & Johnson 3:57 PM 4:09 PM TAXOMET: A French prospective multicenter randomized controlled phase II study comparing MARC Pujalte Martin 5004 docetaxel plus metformin versus docetaxel plus placebo in mCRPC. 4:09 PM 4:21 PM TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib Lynparza AstraZeneca Joaquin Mateo 5005 for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations. 4:21 PM 4:33 PM Aggressive Therapy for Aggressive Disease Mary-Ellen Taplin 4:33 PM 4:45 PM Panel Question and Answer Panel Discussion 4:45 PM 4:57 PM First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus Erleada Johnson & Johnson Kim N. Chi 5006 placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). 4:57 PM 5:09 PM Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial Xtandi; Xofigo Astellas; Bayer Bertrand F. Tombal 5007 comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis. 5:09 PM 5:21 PM Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and Xtandi; Zytiga Astellas; Johnson & Michael J. Morris 5008 prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). Johnson 5:21 PM 5:33 PM Androgen Targeted Therapy: Is More Better? Michael Anthony 5:33 PM 5:45 PM Panel Question and Answer Panel Discussion Oral Abstract Session Head and Neck Cancer Location: E450 2:45 PM 5:45 PM Chair - Head and Neck Cancer Assuntina Gesualda Sacco 2:45 PM 5:45 PM Chair - Head and Neck Cancer Xiuning Le 2:45 PM 2:57 PM Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first- Keytruda Merck & Co. Danny Rischin 6000 line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). 2:57 PM 3:09 PM Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results Kadcyla Roche Bob T. Li 6001 from a phase II basket trial. 3:09 PM 3:21 PM TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and Joel Guigay 6002 neck squamous cell carcinoma (R/M HNSCC). 3:21 PM 3:33 PM The Three Pillars of Systemic Therapy Vanita Noronha 3:33 PM 3:45 PM Panel Question and Answer Panel Discussion 3:45 PM 3:57 PM Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy Jun Ma 6003 (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial. 3:57 PM 4:09 PM Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent Ming-Yuan Chen 6004 chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicenter randomized controlled trial. 4:09 PM 4:21 PM Believe it or Not! Intensification of Therapy for Nasopharynx Cancer A. Dimitrios Colevas 4:21 PM 4:33 PM Panel Question and Answer Panel Discussion 4:33 PM 4:45 PM A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: Radiotherapy Anthony Charles Nichols 6006 versus trans-oral robotic surgery (ORATOR). 4:45 PM 4:57 PM Neck dissections based on sentinel lymph node navigation versus elective neck dissections in early Yasuhisa Hasegawa 6007 oral cancers: A randomized, multicenter, non-inferiority trial. 2019 ASCO Annual Meeting Planner Friday, May 31 - Oral Presentations Start End Title Drug Company Presenter Abstract # 4:57 PM 5:09 PM Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results. Imfinzi; AstraZeneca Renata Ferrarotto 6008 tremelimumab 5:09 PM 5:21 PM Three Ways That Less May Be More: Deintensifying Surgery St. John Maie 5:21 PM 5:33 PM Panel Question and Answer Panel Discussion Oral Abstract Session Health Services Research, Clinical Informatics, and Quality of Care Location: S102 2:45 PM 5:45 PM Chair - Health Services Research, Clinical Informatics, and Quality of Care Jimmy Ruiz 2:45 PM 5:45 PM Chair - Health Services Research, Clinical Informatics, and Quality of Care Erica T. Warner 2:45 PM 2:57 PM Effect of montelukast and rupatadine on rituximab infusion time, rate, severity of reactions, and cost Singulair; Rupafin; Merck & Co.; Uriach; Rouslan Kotchetkov 6500 of administration. Rituxan Roche 2:57 PM 3:09 PM Comparison of normal saline versus heparin flush solutions for maintaining patency of central Amy Pai 6501 venous catheter in cancer patients. 3:09 PM 3:21 PM Preventing excess narcotic prescriptions in MIS urologic oncology discharges (PENN): A prospective Ruchika Talwar 6502 cohort quality improvement initiative. 3:21 PM 3:33 PM Significance of examined lymph node number in accurate staging and long-term survival in resected Lei Huang 6503 stage I-II pancreatic cancer: More is better? A large international population-based cohort study. 3:45 PM 3:57 PM Panel Question and Answer Panel Discussion 3:57 PM 4:09 PM Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic Keytruda; Opdivo Merck & Co.; Bristol- Evan Thomas Hall 6504 cancer center. Myers Squibb 4:09 PM 4:21 PM A process to reduce hospital admissions in the OCM population through focused intervention of Manuel Perry 6505 super-utilizers. 4:21 PM 4:33 PM The financial impact of physician practice patterns: An analysis of as-needed filgrastim versus Christine Barrett 6506 prophylactic pegfilgrastim in patients with prostate cancer receiving docetaxel. 4:33 PM 4:45 PM Costs Matter: Strategies for Success Kerin B. Adelson 4:45 PM 4:57 PM Panel Question and Answer Panel Discussion 4:57 PM 5:09 PM Quality of end-of-life cancer care at minority-serving US cancer centers: A retrospective study of Garrett Wasp 6507 Medicare claims data. 5:09 PM 5:21 PM Impact of a same-day breast biopsy program on disparities in time to biopsy. Matthew Seidler 6508 5:21 PM 5:33 PM Disparities: Measurement to Action Erica T. Warner 5:33 PM 5:45 PM Panel Question and Answer Panel Discussion Oral Abstract Session Pediatric Oncology I Location: S504 2:45 PM 5:45 PM Chair - Pediatric Oncology I Margaret E Macy 2:45 PM 5:45 PM Chair - Pediatric Oncology I Melinda Gordon Pauly 2:45 PM 2:57 PM Randomized phase 2 trial of the combination of vincristine and irinotecan with or without Anne Sophie 10000 temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS). Defachelles 2:57 PM 3:09 PM Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk Lucas Moreno 10001 neuroblastoma (RR-HRNB): Results of the BEACON-Neuroblastoma randomized phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC) - International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial. 3:09 PM 3:21 PM Chemotherapy Combinations for Solid Tumors: The Whole Is Not Greater Than the Sum of the Parts Lars M.